Navigation Links
Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
Date:3/14/2012

In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.

This potential new drug target belongs to a class of receptors called the nicotinic acetylcholine receptors (nAChRs). One subtype of nAChRs, called alpha4beta2 is a well-known target for nicotine's addictive effects and the therapeutic effect of the smoking cessation drug varenicline. SRI researchers are now studying another, lesser-known subtype, called alpha3beta4 nAChR, which has recently shown to play a role in the addictive properties of cocaine, morphine, and nicotine.

Using AT-1001, a highly selective alpha3beta4 compound developed by Astraea Therapeutics, SRI researchers found that addiction processes could be disrupted. In preliminary studies, AT-1001 also reduced nicotine withdrawal symptoms such as anxiety.

Because addictive drugs act on the brain's "reward circuit," many people compulsively take them despite their harmful consequences. Feelings of pleasure are caused by the release of brain chemicals, or neurotransmitters, and their increased activity in the brain reward circuit. The key neurotransmitter in the reward circuit is dopamine, which produces changes in addictive behavior. Researchers speculate that disruption of the alpha3beta4 nAChR system using highly selective drugs such as AT-1001 may interrupt this reward circuitry.

"Currently, there are no therapeutics approved to treat addiction to stimulants such as cocaine, so it is intriguing to find a promising drug receptor target and to see that AT-1001 can indeed affect phenomena that are thought to be deeply tied to the addictive nature of cocaine and other drugs of abuse," said Taline Khroyan, Ph.D., Senior Behavioral Pharmacologist in SRI's Center for Health Sciences.

Findings from these collaborative studies were recently presented at the Society for Neuroscience Annual Meeting in a study titled "AT-1001, a Highly Selective alpha3beta4 nicotinic Receptor Antagonist is Effective in Blocking Place Preference, Behavioral Sensitization, and Withdrawal Effects of Various Drugs of Abuse." The presentation was highlighted by the Society for describing the innovative approach taken by the research team.


'/>"/>

Contact: Dina Basin
dina.basin@sri.com
650-859-3845
SRI International
Source:Eurekalert

Related biology news :

1. New mouse collaborative cross resource promises new cures and treatments for diseases
2. Collaborative Health Consortium Announces eCollaboration Forum Final Agenda for HIMSS 2012
3. Collaborative effort uncovers DNA duplications that may be responsible for genomic-based diseases
4. DFG to fund 8 new collaborative research centers
5. BGI announces collaborative research agreements with Oregon State University
6. UCSB awarded $15 million by Dow to establish collaborative institute for materials research and education
7. Louisiana State University leads collaborative effort to identify genes supporting life in extreme conditions
8. Danforth Center Collaborative Research Program receives funding to improve crop yield in Africa
9. UNC-Duke ties lead to collaborative finding about cell division & metabolism
10. The first studies utilizing the Collaborative Cross mice are published in Genome Research
11. Mouse virus erroneously linked to chronic fatigue syndrome, UCSF collaborative study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to ... , Doug began his career at PBI-Gordon in February 1988, after finishing his ... variety of roles, ranging from customer service to national product manager, to helping develop, ...
(Date:5/3/2016)... ... 03, 2016 , ... Morf Media Inc ., developer ... on mobile devices, today released a new interactive Food and Drug Administration ... course is essential for owners or operators of places of business that are ...
(Date:5/3/2016)... ... 03, 2016 , ... Flagship Biosciences, the leader in ... Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, ... Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 ...
(Date:5/3/2016)... 2016 - And Other Rising ... of Those Competitor Biologics  - Biosimilar Drug ... Prospects ,  Who are the most important ... are their sales potentials? Discover, in our updated survey, ... opportunities and revenue forecasting. Visiongain,s ...
Breaking Biology Technology: